EVGN

+ Watchlist + Portfolio

Evogene Ltd.

Regulated industry Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.44
52-Week Range: $0.35 – $1.50
Market Cap: $6.72M
P/E (TTM): —
EPS (TTM): -1.55
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -182.75%
Return on Assets: -37.53%
Gross Margin: -67.59%
Operating Margin: -606.63%
Profit Margin: 0.00%
Current Ratio: 3.57
Debt/Equity: 0.36
Total Debt: $2.10M
Free Cash Flow: $-1.98M
Revenue Growth: -60.70%
Earnings Growth: —
Enterprise Value: $7.60M

EVGN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.68M	$2.98M	$5.58M	$3.85M
Cost of Revenue	$909.00K	$1.49M	$2.38M	$4.09M
Gross Profit	$766.00K	$1.49M	$3.20M	-$241.00K
Research & Development	$20.79M	$16.20M	$12.51M	$7.99M
Selling, General & Admin	$10.41M	$7.53M	$8.98M	$5.76M
Operating Expenses	$27.71M	$23.70M	$21.95M	$13.79M
Operating Income	-$26.94M	-$22.20M	-$18.76M	-$14.03M
EBITDA	-$27.01M	-$20.53M	-$13.36M	-$12.20M
Pretax Income	-$29.75M	-$21.95M	-$14.81M	-$13.50M
Income Tax	$90.00K	$19.00K	$9.00K	$1.00K
Net Income	-$26.64M	-$23.88M	-$16.48M	-$8.48M
Diluted EPS	-6.50	-5.20	-2.89	-1.08
Diluted Shares	4.12M	4.57M	5.70M	7.87M

EVGN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$28.98M	$20.77M	$15.30M	$12.96M
Receivables	$803.00K	$804.00K	$1.49M	$1.38M
Inventory	$566.00K	$76.00K	$1.82M	$210.00K
Current Assets	$37.75M	$34.47M	$21.59M	$15.63M
Total Assets	$56.13M	$51.10M	$39.86M	$20.05M
Current Liabilities	$5.63M	$6.94M	$18.70M	$3.44M
Long-Term Debt	$10.11M	$10.37M	—	—
Total Debt	$11.93M	$11.51M	$12.87M	$2.20M
Total Liabilities	$21.34M	$22.42M	$25.03M	$8.07M
Retained Earnings	-$233.71M	-$257.59M	-$274.07M	-$282.56M
Shareholders' Equity	$27.93M	$12.05M	-$1.45M	-$82.00K
Working Capital	$32.13M	$27.52M	$2.89M	$12.19M

EVGN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$23.68M	-$21.58M	-$19.70M	-$13.50M
Capital Expenditure	-$1.17M	-$577.00K	-$626.00K	-$135.00K
Free Cash Flow	-$24.85M	-$22.15M	-$20.33M	-$13.64M
Depreciation & Amortisation	$2.58M	$1.30M	$1.38M	$1.14M
Stock-Based Compensation	$1.19M	$1.11M	$1.24M	$654.00K
Investing Cash Flow	$13.27M	-$4.54M	$9.62M	$17.74M
Financing Cash Flow	$9.34M	$18.15M	$4.66M	-$6.60M
Net Change in Cash	-$1.06M	-$7.96M	-$5.42M	-$2.37M

EVGN Income statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$1.61M	$2.34M	$534.00K	$312.00K	$314.00K	$334.00K	$347.00K
Cost of Revenue	$755.00K	$1.52M	$136.00K	$157.00K	$2.28M	$130.00K	$206.00K
Gross Profit	$856.00K	$826.00K	$398.00K	$155.00K	-$1.97M	$204.00K	$141.00K
Research & Development	$3.40M	$2.47M	$1.67M	$1.38M	$1.83M	$1.84M	$1.37M
Selling, General & Admin	$2.02M	$1.57M	$1.34M	$1.50M	$1.20M	$1.54M	$1.21M
Operating Expenses	$5.42M	$3.85M	$3.01M	$2.88M	$3.24M	$3.35M	$2.70M
Operating Income	-$4.57M	-$3.03M	-$2.61M	-$2.72M	-$5.21M	-$3.15M	-$2.56M
EBITDA	-$2.54M	-$1.14M	-$2.19M	-$1.99M	-$6.46M	-$1.82M	-$1.27M
Pretax Income	$2.00K	-$1.90M	-$3.01M	-$2.73M	-$5.34M	-$5.91M	-$1.59M
Income Tax	$7.00K	$0.00	$1.00K	$1.00K	$0.00	$4.00K	$0.00
Net Income	$427.00K	-$2.59M	-$4.46M	$3.87M	-$5.31M	-$5.87M	-$1.77M
Diluted EPS	0.06	-0.38	-0.62	0.44	-0.61	-0.60	-0.14
Diluted Shares	6.80M	6.80M	7.23M	8.72M	8.72M	9.74M	12.20M

EVGN Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$7.50M	$7.50M	$8.33M	$5.63M	$12.96M	$8.51M	$9.32M
Receivables	$3.29M	$3.29M	$1.79M	$1.99M	$1.38M	$1.70M	$1.41M
Inventory	$2.15M	$2.15M	$1.96M	$2.11M	$210.00K	$175.00K	$93.00K
Current Assets	$16.50M	$16.50M	$28.64M	$20.83M	$15.63M	$14.96M	$10.85M
Total Assets	$34.30M	$34.30M	$33.93M	$26.09M	$20.05M	$17.95M	$13.44M
Current Liabilities	$15.60M	$15.60M	$15.19M	$4.08M	$3.44M	$5.36M	$3.04M
Total Debt	$12.96M	$12.96M	$12.69M	$2.52M	$2.20M	$2.03M	$2.10M
Total Liabilities	$21.91M	$21.91M	$21.55M	$8.83M	$8.07M	$9.96M	$7.67M
Retained Earnings	-$276.66M	-$276.66M	-$281.12M	-$277.25M	-$282.56M	-$288.43M	-$290.19M
Shareholders' Equity	-$3.65M	-$3.65M	-$3.55M	$1.14M	-$82.00K	-$2.54M	-$3.29M
Working Capital	$902.00K	$902.00K	$13.45M	$16.76M	$12.19M	$9.60M	$7.81M
Net Debt	$2.88M	$2.88M	$1.70M	—	—	—	—

EVGN Cash Flow statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$5.21M	-$5.18M	-$2.30M	-$3.33M	-$2.69M	-$2.95M	-$1.97M
Capital Expenditure	-$322.00K	-$121.00K	-$2.00K	-$6.00K	-$6.00K	-$2.00K	-$9.00K
Free Cash Flow	-$5.53M	-$5.30M	-$2.30M	-$3.34M	-$2.69M	-$2.96M	-$1.98M
Depreciation & Amortisation	$593.00K	$310.00K	$245.00K	$281.00K	$263.00K	$202.00K	$149.00K
Stock-Based Compensation	$317.00K	$238.00K	$219.00K	$27.00K	$155.00K	-$9.00K	$93.00K
Investing Cash Flow	$8.76M	-$2.44M	-$989.00K	$10.91M	$10.26M	-$4.49M	$4.62M
Financing Cash Flow	$440.00K	-$159.00K	$4.15M	-$10.34M	-$256.00K	$2.99M	-$1.84M
Dividends Paid	—	—	$0.00	—	—	-$193.00K	-$2.48M
Net Change in Cash	$3.99M	-$7.79M	$859.00K	-$2.76M	$7.32M	-$4.45M	$810.00K

Market Snapshot

About

Evogene Ltd. is a computational biology company leveraging big data and artificial intelligence to discover and develop products in multiple life-science based industries. The company's proprietary technology platform uses computational predictive biology and large-scale data analytics to improve the development of seeds, microbes, small molecules, and ag-chemicals. Evogene operates through several subsidiaries targeting different markets including agriculture, industrial applications, and human health. The company's AI-driven approach accelerates product discovery and development while reducing costs and time to market. Headquartered in Israel, Evogene represents a technology-driven approach to life sciences innovation.